Abstract
Chimeric anti-CD20 monoclonal antibody rituximab is a standard component of treatment in most CD-20-positive non-Hodgin's lymphomas. Rituximab is most frequently combined with chemoptherapy (i.e, immunochemotherapy) and is also as a maintenance treatment in follicular and mantle cell lymphoma patients with the aim of progression-free survival and overall survival prolongation.
Rituximab is currently approved for intravenous infusion only. However, based on promosing clinical data, subcutaneous administration seems to be safe and effective.
The eim of this rewiev is to summarize current data about subcutaneous administration of rituximab in lymphoma patients in terms of safety, efficacy and potential benefits of this approach.